1[1]Wolff JA,Malone RW,Williams P,et al.Directed gene transfer into mouse muscle in vivo[J].Science,1990,247(2):1465-1468.
2[2]Babiuk LA,van Drunen Littel-van den H,Babiuk SL.Immunization of animals:from DNA to the dinner plate[J].Vet Immunol Immunopathol,1999,72(1～2):189-202.
3[3]Barouch DH,Santra S,Schmitz JE,et al.Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination[J].Science,2000,290(5491):486-492.
4[4]Xin KQ,Hamajima K,Sasaki S,et al.Intranasal administration of human immunodeficiency virus type-1(HIV-1)DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1[J].Immunology,1998,94(3):438-444.
5[5]Chow YH,Huang WL,Cli WK,et al.Improvement of hepatitis B virus DNA vaccine by plasmids coexpressing hepatitis B surface antigen and interleukin 2[J].J Virol,1997,71(1):169-178.
6[6]Chow YH,Chiang BL,Lee YL,et al.Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes[J].J Immunol,1998,160(3):1320-1329.
7[7]Rakhmilevich AL.Cytokine gene therapy of cancer using gene technology:superior antitumor activity of interleukin-12[J].Hum Gene Ther,1997,8(11):1303-1311.
8[8]Gherardi MM,Ramirez JC,Esteban M.Towards a new generation of vaccine:the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens[J].Histol Histopathol,2001,16(2):655-667.
9[9]Tsuji T,Hamajima K,Fukkushima J,et al.Enhancement of cell-mediated immunity against HIV-1 induced by coinoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12[J].J Immunol,1997,158(8):4008-4013.
10[10]Kim JJ,Ayyavoo V,Bagarazzi ML,et al.In vivo engineering of a cellular immune response by coadministration of IL-12 expressing vector with a DNA immunogen[J].J Immunol,1997,158(2):816-826.
二级参考文献19
1成军 陈菊梅.白细胞介素18的研究进展[J].细胞和分子免疫学杂志,1999,15:1-3.
2Ystein B,Mlvestad E. Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation; differences between patients in costimμlatory capacity affect proliferative responsiveness and cytokine release by activated T cells. Cancer Immunol Immunotherapy, 2003, 52:215--225.
3Cameron-Wilson C L, Zhang H, Zhang F, et al. A vector with transcriptional terminators increases efficiency of cloning of an RNA virus by reverse transcription long polymerase chain reaction. J Mol Microbiol Biotechnol,2002,4 : 127-- 131.
4Barouch D H, Santra S, Steenbeke T D, et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol, 1998, 161: 1875--1882.
5Kim J J, Yang J S, Vancott T C, et al. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. JVirol, 2000, 74: 3427--3429.
6Chow Y H, Huang W L, Chi W K, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. JVirol, 1997, 71: 169-178.
7Loza M J, Zamai L, Azzoni L, et al. Expression of type 1 (interferon gamma) and lype 2 (inlerleukin-13,interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood,2002, 99:1273--1281.
8Rodella L, Zamai L, Rezzani R, et al. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br J Haematol, 2001,115 :442--450.
9Donnelly JJ, Ulmer JB, Liu MA. DNA vaccine[J]. Life Sci, 1997,60:163 - 172.
10Schild GC, Minor PD. Human immunodeficiency virus and AIDS vaccine[J]. Lancet, 1990, 335:1081-1084.
1Cheever MA,Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J].Clinical Cancer Research,2011,(11):3520-3526.
2Riedmann EM. Two years of Provenge[J].Hum Vaccin Immunother,2012,(04):505.
3Madan RA,Gulley JL. Sipuleucel-T:harbinger of a new age of therapeutics for prostate cancer[J].Expert Review of Vaccines,2011,(02):141-150.
4Parmiani G,Castelli C,Pilla L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients[J].Annals of Oncology,2007,(02):226-232.
5Olivares J,Kumar P,Yu Y. Phase Ⅰ trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine[J].Clinical Cancer Research,2011,(01):183-192.
6Okada H,Lieberman FS,Walter KA. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas[J].Journal of Traditional Medicines,2007,(19):67-77.
7Slingluff CJ. The present and future of peptide vaccines for cancer:single or multiple,long or short,alone or in combination[J].Cancer Journal,2011,(05):343-350.
8Becker JC,Andersen MH,Hofmeister-Muller V. Survivinspecific T-cell reactivity correlates with tumor response and patient survival:a phase-Ⅱ peptide vaccination trial in metastatic melanoma[J].Cancer Immunology, Immunotherapy,2012,(11):2091-2103.
9Schwartzentruber DJ,Lawson DH,Richards JM. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma[J].New England Journal of Medicine,2011,(22):2119-2127.
10Baba T,Sato-Matsushita M,Kanamoto A. Phase Ⅰ clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A * 2402[J].Journal of Traditional Medicines,2010,(01):84-95.
